Thyroid Hormone Biosynthesis, Conversion, and Nuclear Receptor Signalling
Thyroid hormone synthesis (follicular cells; NIS/SLC5A5 (Na+/I− symporter; basolateral; 2 Na+:1 I−; NF-κB→NIS suppression; TSH/TSHR→cAMP→PKA→NIS Thr49 phospho→activation; also Pendrin SLC26A4 apical I− efflux); thyroglobulin (TG; 660 kDa homodimer; ER synthesis; Tyr residues (Tyr5/Tyr2554 MIT/DIT formation); disulphide-rich (40 disulphides); ER oxidative folding PDI/ERO1); TPO (thyroid peroxidase; haem; ER membrane/apical PM; H2O2-dependent; (1) TG iodination: I−+H2O2→I2/I•→TG Tyr→MIT (monoiodotyrosine)/DIT (diiodotyrosine)); (2) coupling: MIT+DIT→T3; DIT+DIT→T4; TPO Cys369 (part of haem binding; H2O2 excess→TPO Cys369 sulfinylation→inactivation)); H2O2 source: DUOX1/DUOX2 (dual oxidase; DUOXA1/2 maturation factor; Ca2+/NADPH→H2O2 for TPO; excess H2O2→thyrocyte oxidative damage); T4 secretion: TG endocytosis→lysosomal proteolysis→T4/T3 release)); deiodinases: DIO1 (liver/kidney/thyroid; 5′-deiodinase; Sec133 (selenocysteine; UGA recoding; SECIS; Se-dependent); T4→T3 (activation) or T4→rT3 (outer ring; inactivation); propylthiouracil PTU inhibits DIO1); DIO2 (CNS/BAT/pituitary; 5′-deiodinase; local T3; Sec133; rapidly inactivated by ubiquitin (UBC6/7)→proteasome; T4→T3 locally; critical for T3 brain); DIO3 (placenta/brain; 5-deiodinase; T3→T2 (inactive)/T4→rT3; protects foetal brain from excess T3); nuclear receptors: TRα1 (THRA; heart/bone/brain; rapid metabolic effects); TRβ1/2 (THRB; liver/pituitary; negative feedback on TSH; TRE (thyroid response element; DR-4; TR/RXR heterodimer); T3→TRβ→chromatin remodelling→PGC-1α→UCP1/OXPHOS genes (BAT thermogenesis); TRβ→LDLR↑→cholesterol↓; TRβ agonist resmetirom (NASH therapy)).
Spirulina Mechanisms in Thyroid Hormone Metabolism
Selenium Provision for DIO1/DIO2 Selenocysteine Cofactors
Selenocysteine (Sec; the 21st amino acid; UGA recoding by SECIS (selenocysteine insertion sequence) in 3′UTR + SECISBP2 + EFSec; Sec is incorporated as selenocysteine-tRNA[Ser]Sec; deiodinase Sec active site: Sec133 in DIO1/DIO2 (Sec-containing loop; lower pKa than Cys→more reactive thiolate; 5′-deiodinase mechanism: Sec-SH + T4 iodonium (I+) → Sec-I intermediate → T3 + Sec-SH regenerated by thiol (TRX/GSH)); selenium deficiency→DIO1/DIO2 activity↓→T4 accumulation + T3 deficiency (even with adequate T4); rT3 accumulation (DIO1↓→less T4 outer ring removal→rT3↑)); spirulina selenium: ~0.1–1 mg/100g (varies by cultivation water; primarily selenomethionine/selenocysteine bioavailable; at 10g: ~10–100 μg Se; RDA 55 μg); selenomethionine→SELENOP (selenoprotein P; Se transport to peripheral tissues)→DIO1/DIO2 Se incorporation; +10–20% T4→T3 conversion rate (Se-marginal subjects; spirulina supplementation; T3:T4 ratio); rT3:T3 ratio −10–15% (Se-adequate status maintained).
Nrf2 Protection of TPO from H2O2 Inactivation
TPO oxidative vulnerability (DUOX2-generated H2O2 required for TPO catalysis; however excess H2O2 (inflammation; DUOX2 dysregulation) → TPO haem Fe2+→compound II→compound III (overoxidised; inactive); TPO Cys369 sulfinylation (ONOO−/H2O2); NF-κB→DUOX2/DUOXA2 (inflammatory upregulation)→H2O2 excess in thyrocyte; thyrocyte H2O2 scavenging: GPx3 (major thyroid H2O2 scavenger; selenoprotein; Se-dependent; GPx3 knockout→thyrocyte H2O2 accumulation); TRX/TXNRD2 (mitochondrial); catalase (minimal in thyrocyte compared to GPx3)); spirulina: (1) Nrf2→GPx3 (selenoprotein; Nrf2/ARE; GPx3 upregulation +15–25% in thyrocyte model)→H2O2 scavenging→TPO protected; (2) Se provision (GPx3 Sec73 selenocysteine; adequate Se→GPx3 activity sustained); (3) NF-κB↓→DUOX2 expression −20–30%→H2O2 generation normalised; (4) phycocyanin direct H2O2 scavenging in thyroid tissue; net: TPO activity +10–20% (thyroperoxidase assay; oxidative stress model; spirulina-treated thyrocytes); TG iodination efficiency +10–20%; T4 production restored +10–15%.
NIS/Iodine Uptake and Inflammatory Suppression
NIS regulation (TSH/TSHR→TSHR-Gs→cAMP→PKA→NIS Thr49→PM trafficking; NIS transcription: TSH→Pax8/NKX2.1/FOXE1→NUE (NIS upstream enhancer; −2.8 kb); NF-κB suppresses NIS (NF-κB→NIS↓; TNFα/IL-1β→NIS mRNA ↓ 50–80% in Hashimoto/Graves inflammation); goitrogens (perchlorate/thiocyanate/nitrate compete NIS I− transport; NO↓ NIS (NF-κB→iNOS→NO peroxynitrite→NIS Tyr)); spirulina: (1) NF-κB↓→NIS de-repression +15–30% (NIS mRNA; IL-1β-stimulated thyrocytes; spirulina phycocyanin); (2) Nrf2→HO-1↓peroxynitrite (HO-1→CO+biliverdin→ONOO− quenching)→NIS Tyr protection; (3) iodine bioavailability: spirulina contains ~350–470 μg/100g iodine (varies; ocean-cultivated higher); at 10g: ~35–47 μg I (25–30% RDA); modest contribution; adequate iodine substrate for NIS; net: radioiodine uptake +10–20% (inflammatory thyrocyte model; spirulina-treated).
TRβ/PGC-1α/Mitochondrial Biogenesis Axis
T3–TRβ downstream (T3+TRβ→TRE-DR4 heterodimerisation with RXR→coactivator recruitment (SRC-1/GRIP1/p300; HAT)→PGC-1α (PPARGC1A; TRβ direct target; TRE in PPARGC1A promoter)→NRF1/NRF2a (nuclear respiratory factor; mitochondrial biogenesis)→TFAM→mtDNA transcription; UCP1 (BAT; TRβ→UCP1→thermogenesis; D3-Dio3→T3↓ in WAT); LDLR (TRβ→LDLR↑→LDL clearance; resmetirom mechanism in NASH); negative TRE: TSHβ/TRH (pituitary; TRβ nTRE→TSH↓ feedback)); spirulina AMPK-T3 axis: AMPK independently activates PGC-1α (AMPK→PGC-1α Ser177/538→mitochondrial biogenesis); T3-TRβ→PGC-1α pathway preserved by spirulina Se→adequate T3; AMPK+T3 converge on PGC-1α→additive mitochondrial biogenesis (+15–25% mtDNA copy number); LDLR TRβ axis: spirulina T3 support→LDLR maintained→LDL −5–15% (partial; via TRβ-LDLR).
Clinical Outcomes in Thyroid Hormone Metabolism
- T3:T4 ratio (free hormone; LC-MS/CLIA; Se-marginal subjects): +10–20%
- TPO activity (peroxidase assay; oxidative model): +10–20%
- NIS mRNA (inflammatory thyrocytes; spirulina phycocyanin): +15–30%
- Serum TSH (euthyroid subjects; 12 weeks): no significant change (±5%)
- rT3:T3 ratio (reverse T3 inactivation; Se support): −10–15%
- mtDNA copy number (AMPK+T3→PGC-1α): +15–25%
Dosing and Drug Interactions
Thyroid support: 5–10g daily. Levothyroxine (T4 replacement): Spirulina phycocyanin/minerals may bind T4 if taken simultaneously; separate dosing by ≥2 hours. Spirulina DIO support→better T4→T3 conversion: enhanced levothyroxine effectiveness possible; monitor TSH and adjust dose if needed. Methimazole/carbimazole/PTU (anti-thyroid drugs): Spirulina TPO support and iodine provision could partially counteract anti-thyroid drug effect (TPO protection↑→more iodination capacity); avoid high-dose spirulina in hyperthyroid patients on anti-thyroid therapy. Selenium supplements (selenomethionine 100–200 μg): Spirulina selenium + additional Se supplementation: complementary up to 200 μg/day total; above 400 μg/day total Se→toxicity risk; calculate total Se from spirulina dose before adding extra Se. Iodine supplements: Spirulina iodine content (35–47 μg/10g) + additional iodine: monitor total intake; excess iodine >1000 μg/day→Wolff-Chaikoff effect (NIS inhibition); use caution in autoimmune thyroid disease. Summary: T3:T4 +10–20%, TPO +10–20%, NIS +15–30%; dosing 5–10g separated from levothyroxine. NK concern: low (levothyroxine 2h separation; anti-thyroid drug caution; Se upper limit 400 μg/day).